{"denoms":[{"counts":[{"groupId":"BG000","value":"223"},{"groupId":"BG001","value":"222"},{"groupId":"BG002","value":"445"}],"units":"Participants"}],"groups":[{"description":"Patients receive oral lenalidomide once daily on days 1-21, oral aspirin (or other deep vein thrombosis prophylaxis at the discretion of the principal investigator) once daily on days 1-28, and standard-dose oral dexamethasone once daily on days 1-4, 9-12, and 17-20. Patients with minimal response or no response after 4 cycles of treatment could register for Step 2 treatment with thalidomide and high-dose dexamethasone. Thalidomide was given orally once daily on days 1-28, and dexamethasone once daily on days 1-4, 9-12, and 17-20 for 4 cycles.\n\nAs the expansion phase was a substudy terminated early with only 7 patients enrolled, the clinical results presented are mainly for the first phase only. Toxicity data are available for both the first phase and the expansion phase.","id":"BG000","title":"Arm I (Lenalidomide, Dexamethasone)"},{"description":"Patients receive oral lenalidomide and acetylsalicylic acid as in arm I and low-dose oral dexamethasone once daily on days 1, 8, 15, and 22. Patients with minimal response or no response after 4 cycles of treatment could register for Step 2 treatment with thalidomide and low-dose dexamethasone. Thalidomide was given orally once daily on days 1-28, and dexamethasone once daily on days 1, 8, 15, and 22 for 4 cycles.\n\nAs the expansion phase was a substudy terminated early with only 7 patients enrolled, the clinical results presented are mainly for the first phase only. Toxicity data are available for both the first phase and the expansion phase.","id":"BG001","title":"Arm II (Lenalidomide, Low-dose Dexamethasone)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"36","upperLimit":"87","value":"66"},{"groupId":"BG001","lowerLimit":"35","upperLimit":"85","value":"65"},{"groupId":"BG002","lowerLimit":"35","upperLimit":"87","value":"65"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"101"},{"groupId":"BG002","value":"192"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"121"},{"groupId":"BG002","value":"253"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}